USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
31 Aug 2023 | 03:00 PM GMT

Evidence Generation: What payers are looking for

Anchored by:

Leonardo Angelone
Deputy Director
THE NATIONAL INSTITUTES ON DRUG ABUSE

Participants:

Leonardo Angelone Deputy DirectorThe National Institutes on Drug Abuse
Leonardo Angelone
Deputy DirectorThe National Institutes on Drug Abuse
Rick Bartels President/Founder DTxCC
Rick Bartels
President/Founder DTxCC
Benjamin Alouf Chief Medical OfficerFloreo
Benjamin Alouf
Chief Medical OfficerFloreo
Jess Lukacs Business Development Program OfficerThe National Institute on Drug Abuse (NIDA)
Jess Lukacs
Business Development Program OfficerThe National Institute on Drug Abuse (NIDA)
Jordan Silberman Dir of Clinical Analytics & ResearchElevance Health
Jordan Silberman
Dir of Clinical Analytics & ResearchElevance Health
Mark Prueter National Director, Employer & Benefit Strat.Otsuka Pharmaceuticals America
Mark Prueter
National Director, Employer & Benefit Strat.Otsuka Pharmaceuticals America
Mark Grossman VP of Growth Initiatives & Market PartnersGoMo Health - Engagement that Works
Mark Grossman
VP of Growth Initiatives & Market PartnersGoMo Health - Engagement that Works
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected Health
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Ralph Morales III Managing DirectorShokunin Ventures
Ralph Morales III
Managing DirectorShokunin Ventures
Renae Beaumont Associate Professor of PsychologyWeill Cornell Medicine
Renae Beaumont
Associate Professor of PsychologyWeill Cornell Medicine
Ventsislav Dobrev Global Clinical Lead Digital BiomarkersRoche
Ventsislav Dobrev
Global Clinical Lead Digital BiomarkersRoche

About this Meeting

Establishing the effectiveness of your solutions and securing reimbursement can be a daunting task. In the evolving reimbursement landscape, presenting a compelling value proposition and robust evidence base becomes crucial. However, not all payers demand the same type and level of evidence. This presents a significant hurdle for digital health companies who may operate on limited budgets as they design their evidence generation strategies. 

To overcome these challenges, it is imperative for digital health innovators to explore effective pathways that align with evidence standards and provide efficient routes to national scale.

In this interactive session, we will delve into the evolving reimbursement landscape and unravel evidence demands of different payers. Considerations we will cover include: 

  • How different payers evaluate the clinical and economic value of digital health solutions. 
  • Strategies to align your evidence generation efforts with the specific requirements of each payer segment.
  • How to maximise your investment and future proof your evidence generation strategy. 
We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.